Epinastine is an antihistamine used primarily for allergic conditions, such as allergic conjunctivitis, and is unrelated to HIV treatment. Unlike abacavir, which is a nucleoside reverse transcriptase inhibitor for HIV, epinastine works by blocking histamine H1 receptors to reduce symptoms like itching, redness, and swelling in the eyes or nasal passages. It was developed in the 1980s–1990s for allergy management and is commonly formulated as eye drops or oral preparations, depending on the indication. Epinastine is generally well-tolerated, with mild side effects such as bitter taste, headache, or eye irritation, and does not require genetic screening before use.
BRAND NAMES
Elestat – ophthalmic drops (eye allergy)
Relestat – used in some countries as eye drops
Epinastine hydrochloride – generic formulations
MECHANISM OF ACTION
Epinastine is a selective histamine H1 receptor antagonist that works by blocking H1 receptors on cells in the eyes or nasal mucosa, preventing histamine from triggering allergic symptoms such as itching, redness, swelling, and tearing.
PHARMACOKINETICS
Absorption
Epinastine, when administered as ophthalmic drops, has minimal systemic absorption due to its local action in the eyes. Only a small fraction enters the systemic circulation through the conjunctival and nasal mucosa.
Distribution
After ocular administration, epinastine primarily remains in the tear film and conjunctival tissues, providing local therapeutic effects. Systemically absorbed amounts are minimal, but when present in the bloodstream, epinastine exhibits moderate plasma protein binding.
Metabolism
Epinastine undergoes minimal systemic metabolism because most of the drug acts locally in the eye. The small fraction that enters systemic circulation is partially metabolized in the liver through oxidative and conjugative pathways, producing inactive metabolites.
Elimination
Epinastine and its metabolites are primarily excreted via the urine, with a smaller portion eliminated in the feces. Following ocular administration, systemic exposure is minimal, so most of the drug’s activity is local, and only trace amounts undergo renal clearance.
PHARMACODYNAMICS
Epinastine exerts its therapeutic effect by selectively antagonizing histamine H1 receptors, preventing histamine from binding and triggering allergic responses in ocular or nasal tissues. It also stabilizes mast cells, inhibiting the release of histamine and other pro-inflammatory mediators, which reduces both immediate and late-phase allergic reactions. Clinically, this results in rapid relief of symptoms such as itching, redness, tearing, and swelling associated with allergic conjunctivitis. The drug acts locally when administered as eye drops, providing high concentrations at the target site with minimal systemic exposure, enhancing safety and tolerability.
ADMINISTRATION
Epinastine is primarily administered as ophthalmic eye drops for the treatment of allergic conjunctivitis. The usual dosing regimen is one drop in each affected eye twice daily, though specific instructions may vary depending on the formulation and patient age. Patients should avoid touching the tip of the dropper to the eye or any surface to prevent contamination.
DOSAGE AND STRENGTH
Epinastine is typically available as a 0.05% ophthalmic solution for the treatment of allergic conjunctivitis. The recommended dosage for adults and children aged three years and older is one drop in each affected eye twice daily, usually in the morning and evening.
DRUG INTERACTIONS
Epinastine has a low potential for drug interactions because it is primarily administered locally as eye drops and undergoes minimal systemic absorption and metabolism. No significant interactions with other medications have been reported in clinical studies.
FOOD INTERACTIONS
Epinastine is administered locally as eye drops, so food intake does not affect its absorption, efficacy, or safety. There are no known food interactions, and patients do not need to adjust meals when using the medication.
CONTRAINDICATIONS
Epinastine is contraindicated in patients with a known hypersensitivity to epinastine or any component of the formulation. It should not be used in individuals with severe ocular infections or eye conditions where histamine blockade may mask underlying issues.
SIDE EFFECTS
Bitter taste
Eye irritation or burning
Headache
Ocular discomfort
Dry eyes
Mild redness of the eyes
TOXICITY
Epinastine has a low toxicity profile due to its local administration and minimal systemic absorption. Most adverse effects are mild and limited to the eyes, such as irritation, burning, redness, or a bitter taste. Systemic toxicity is rare, but in cases of excessive exposure, mild drowsiness or headache may occur.
